Compare Snap On Incorporated (SNA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs Viatris Inc — how do they compare? Snap On Incorporated trades at $407.37 (market cap $21.30B), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: Snap On Incorporated and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| SNA | VTRS | |
|---|---|---|
Market Cap | $21.30B | $18.69B |
Sector | Technology | Health |
52-Week High | $419.31 | $17.86 |
52-Week Low | $321.38 | $9.49 |
Enterprise Value | $20.93B | $30.80B |
Dividend Yield | 2.37% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-on (SNA) trades at $407.04, down 0.99% today, with a bullish technical signal from moving averages and support near $406. The company reported strong Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% and a net income margin of 19.6%. Recent acquisitions like Diesel Laptops for $100 million aim to expand its diagnostics reach.
The outlook remains positive with a consensus price target of $455.33, implying 12% upside, supported by robust cash flow and dividend payments. Key risks include integration costs from acquisitions and premium valuation multiples, while softer OEM demand and economic sensitivity could pressure near-term performance.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
